Urinary angiotensinogen as a marker of intrarenal angiotensin II activity associated with deterioration of renal function in patients with chronic kidney disease

What Was Tested

Researchers studied Angiotensin II in this clinical trial publication.

In chronic kidney disease (CKD), enhanced intrarenal angiotensin II (AngII) is involved in deterioration of renal function, but it is difficult to measure it.

For assessment of the potential of urinary angiotensinogen as a marker of intrarenal AngII activity, the correlation of plasma and urinary renin-angiotensin system components, including angiotensinogen, with deterioration of renal function was investigated in 80 patients who had CKD and were not treated with AngII blocking agents.

Who Took Part

According to the abstract, 80 patients were involved.

By PubMed's age tags, the people studied were teenagers, adults, middle-aged adults, older adults and people over 80, both men and women.

How the Study Was Run

Angiotensinogen was measured by RIA of AngI after incubation with renin.

What Was Measured

In chronic kidney disease (CKD), enhanced intrarenal angiotensin II (AngII) is involved in deterioration of renal function, but it is difficult to measure it.

For assessment of the potential of urinary angiotensinogen as a marker of intrarenal AngII activity, the correlation of plasma and urinary renin-angiotensin system components, including angiotensinogen, with deterioration of renal function was investigated in 80 patients who had CKD and were not treated with AngII blocking agents.

PubMed files the paper under topics including Angiotensin II, Angiotensinogen, Antihypertensive Agents, Biomarkers, Collagen Type I, Kidney and Losartan.

What This Means in Plain Language

This is a clinical trial of Angiotensin II in 80 patients.

The publication is from 2007 (Journal of the American Society of Nephrology : JASN), a journal based in United States.

More context: the Angiotensin II compound page, all human trials.